vp 16-213 ( etoposide , abbr . to vp ) , an oncostatic drug , was administered orally to female crj : cd ( sprague-dawley ) rats from day 17 of gestation through postpartum day 20 at dose levels of 1 , 3 and 10 mg/kg/day .
C0015133
etoposide
C0032961
gestation